Goodwill

The following table sets forth the changes in the carrying amount of goodwill by segment

(in millions):


	BSI Life Science			BSI Nano			BEST		Total

Balance at December 31, 2018	$	72.0		$	203.7		$	—	$	275.7
Current period additions/adjustments		13.1			6.3			0.3		19.7
Foreign currency impact		(0.9	)		(1.5	)		—		(2.4	)

Balance at December 31, 2019		84.2			208.5			0.3		293.0
Current period additions/adjustments		—			13.7			—		13.7
Foreign currency impact		7.9			5.8			—		13.7

Balance at December 31, 2020		92.1			228.0			0.3		320.4
Current period additions/adjustments		13.4			16.6			—		30.0
Foreign currency impact		(5.2	)		(5.7	)		—		(10.9	)

Balance at December 31, 2021	$	100.3		$	238.9		$	0.3	$	339.5

The Company

performed its annual impairment evaluation using both a quantitative and qualitative approach at December 31, 2021, 2020 and 2019, and concluded it was more likely than not that goodwill has not been impaired. Based on the most recent quantitative analysis the fair values of each of the Company’s reporting units was greater than their carrying amounts and, therefore, no impairment was required.

As a result of the impact of the

COVID-19

pandemic, the Company performed an interim impairment assessment of the goodwill balance as of March 31, 2020 using a combination of both quantitative and qualitative approaches. Based on this interim assessment, the Company concluded the fair values of each of the reporting units were significantly greater than their carrying amounts, and therefore, no impairment is required. The goodwill assessment was based on management’s estimates and assumptions, certain of which are dependent on external factors. No further triggering events were identified subsequent to March 31, 2020.

The Company

has recorded $3.1

million of accumulated impairment losses of goodwill as of December 31, 2021.

Intangible Assets

The following is a summary of intangible assets (in millions):


	2021							2020
	Gross					Net		Gross					Net
	Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
	Amount		Amortization			Amount		Amount		Amortization			Amount
Existing technology and related patents	$	310.4	$	(206.8	)	$	103.6	$	309.8	$	(194.6	)	$	115.2
Customer relationships		156.1		(58.2	)		97.9		148.3		(45.4	)		102.9
Trade names		15.5		(5.8	)		9.7		15.2		(4.4	)		10.8
Other		1.8		(1.2	)		0.6		0.3		(0.1	)		0.2

Intangible assets	$	483.8	$	(272.0	)	$	211.8	$	473.6	$	(244.5	)	$	229.1

For the years ended December 31, 2021, 2020 and 2019, the Company recorded amortization expense of approximately $37.4 million, $35.8 million and $38.3 million, respectively, in the consolidated statements of income and comprehensive income.

The estimated future amortization expense related to amortizable intangible assets is as follows (in millions):


2022	$	32.8
2023		29.7
2024		27.5
2025		26.6
2026		28.4
Thereafter		66.8

Total	$	211.8